Spatial and Proteolytic Determinants of Therapeutic Potential in HER2‐Low Breast Cancer

This publication has 10 references indexed in Scilit:

• Proteogenomic Characterization Reveals Subtype‐Specific Therapeutic Potential for HER2‐Low Breast Cancer
  Advanced Science, 2025
• HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers
  Cancers, 2025
• Advances in Immunotherapy for HER2 Low-Expressing Triple-Negative Breast Cancer
  Cancer Management and Research, 2025
• Enhancing HER2-low breast cancer detection with quantitative transcriptomics
  npj Breast Cancer, 2025
• Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
  Nature Communications, 2025
• Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms
  Oncotarget, 2025
• Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
  Medicina, 2024
• Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase–relevant subgroup with therapeutic prospects
  JCI Insight, 2023
• Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
  The Cancer Journal, 2022
• Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
  npj Breast Cancer, 2021